ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Evolution of Imaging Markers of Cartilage Degradation in Patients With Knee Osteoarthritis Receiving DROGLICAN (DRIP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02821468
Recruitment Status : Unknown
Verified June 2016 by Bioiberica.
Recruitment status was:  Recruiting
First Posted : July 1, 2016
Last Update Posted : July 1, 2016
Sponsor:
Collaborator:
Artialis
Information provided by (Responsible Party):
Bioiberica

Brief Summary:

A previous multicenter trial led by Bioiberica S.A. has confirmed the efficacy and safety of DROGLICAN for the treatment of osteoarthritis (OA) in patients with severe pain. The MOVES study was a phase IV, double blind, randomized and non-inferiority trial to compare the efficacy and safety of a fixed dose combination of glucosamine hydrochloride (GH) + chondroitin sulfate (CS) (DROGLICAN) versus celecoxib in patient with symptomatic knee OA with moderate to severe pain. This study concluded that both drugs reduced the WOMAC Pain subscale by 50% without significant difference between groups. Further, there was no difference in all secondary outcomes assessing patient's pain, functional capacity, stiffness, inflammation, joint swelling, effusion, and overall quality of life.

This new exploratory trial is aimed to evaluate the beneficial effect of DROGLICAN on the good health of the cartilage of patients suffering of knee osteoarthritis as revealed by qualitative assessment of cartilage biochemical composition in vivo.


Condition or disease Intervention/treatment Phase
Osteoarthritis, Knee Drug: Droglican Drug: Paracetamol or oral NSAIDs excluding COX2 inhibitors Phase 4

Detailed Description:

This study is a post-marketing, open, exploratory, multicenter trial with 2 parallel-groups of patients suffering from knee OA. Investigators will be private or public hospital rheumatologists, general practitioners, or articular disease specialists located in Belgium.

After evaluation by the investigator during a control visit or via on site-patient registry, potential participants will be asked to perform an inclusion visit (V1). During this visit, the investigator will assess the eligibility of the patients. Eligible patients will sign an informed consent. The investigator will make a general evaluation (demography, medical history, OA history, OA medication history, concomitant medications including "rescue treatments") and a pain evaluation. Synovial fluid will be collected in case of knee swelling.

Blood samples will be collected in a preselected clinical laboratory for future biomarkers analyses.

Patients will be asked to perform an MRI exam within 20 days following the inclusion visit and representing the MRI at baseline. A standard X-ray will be performed at the same imaging site if the last X-ray available is not responding to high quality standard.

For DROGLICAN arm, patients will be given investigational medicinal product (IMP) for a 6-month period via the hospital pharmacy where image acquisition will be performed. IMP intake will begin right after baseline MRI acquisition. Study arm attribution will be determined according to the order of enrolment at each investigating site and using a randomization list.

All study subjects (receiving DROGLICAN or untreated control) will be allowed to take paracetamol and oral NSAIDs excluding COX2 inhibitors to relief knee pain. Patients will be asked to use these "rescue medications" only when needed during the trial, beginning by Paracetamol (up to 3g/day) and NSAIDs as a second-line medication, and will be told to reduce their use if they do not feel the need for them. The use of rescue treatments during the month prior to each visit will be recorded by the investigator in a Case Report Form (CRF). All other treatments for osteoarthritis will be forbidden during the course of the study.

Patients will return for consultation after 6 month (V2) and 12 months (V3). At each visit, the investigator will make a general evaluation, and will record concomitant medications including rescue medications, adverse events and drop-outs.

For DROGLICAN arm, compliance to the IMP will be assessed by counting unused capsules within the investigation kit brought back by the patient. At V2, patients will be given IMP for the next 6 months. Patients will be asked to return to the investigator all unused capsules of IMP at the next visit.

Blood samples and synovial fluid (if applicable) will be collected for future biomarkers analyses. MRI will be done at 6 months (V2) and optionally at 12 months (V3). Finally, an optional X-ray might be performed at V3 depending on the result of the interim analysis.

Monthly phone calls will be made by the investigator to assess and encourage patient's compliance (for DROGLICAN arm), to record potential adverse event, new concomitant treatment and/or drop-off.

Patients' clinical data will be recorded at each visit in a CRF.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Evaluation of the Evolution of Imaging Markers of Cartilage Degradation in Patients With Knee Osteoarthritis Receiving DROGLICAN: a Pilot Study
Study Start Date : June 2016
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : June 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Droglican
Chondroitin Sulfate 1,200mg + Glucosamine Hydrochoride 1,500mg
Drug: Droglican
Combined Chondroitin Sulfate 1200 mg + Glucosamine Hydrochloride 1500 mg

Drug: Paracetamol or oral NSAIDs excluding COX2 inhibitors
Experimental: Control
Untreated arm
Drug: Paracetamol or oral NSAIDs excluding COX2 inhibitors



Primary Outcome Measures :
  1. Evaluate change of composition of cartilage trough imaging marker (dGEMRIC) [ Time Frame: 6 months ]
    To evaluate the techniques for studying proteoglycans content: the delayed gadolinium enhanced magnetic resonance imaging of cartilage (dGEMRIC), after 6 months of treatment with DROGLICAN versus untreated control.


Secondary Outcome Measures :
  1. Consumption of Rescue Medication [ Time Frame: 6 months ]
    Use of rescue treatments (Paracetamol or oral NSAIDs excluding COX2 inhibitors)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Femorotibial knee OA (Uni- or bilateral)
  • Responding to clinical and radiological criteria of American College of Rheumatology (ACR)
  • Symptomatic for more than 6 months in the most painful knee
  • Radiological K&L grade II-III in radiographs from less than 12 months
  • Moderate-to-severe knee pain: knee pain score evaluated on Visual Analogue Scale (VAS) (0-100) ≥ 40 over the last 24 hours at the inclusion visit (the most painful knee is considered)
  • Able to follow the instructions of the study
  • Having signed an informed consent

Exclusion Criteria:

Related to the OA pathology

  • Recent trauma (< 1 month) of the knee responsible of the symptomatic knee
  • Concurrent articular disease interfering with the evaluation of OA and/or pain such as articular dysplasia, aseptic osteonecrosis, acromegaly, Paget's disease, hemophilia, hemochromatosis, chondromatosis, villonodular synovitis of the knee, seronegative spondyloarthropathy, rheumatoid arthritis, gouty arthritis , infectious arthritis, radiculalgia in the lower limbs, arteritis, etc.
  • Radiological K&L grade I or IV
  • Prosthesis in the target knee

Related to treatments

  • Analgesics to manage OA knee pain 24h before inclusion visit
  • Corticosteroids injection in the target knee in the month preceding inclusion
  • Hyaluronan injection in the target knee in the last 6 months
  • Oral corticotherapy ≥ 5mg/day in the last 3 months
  • Symptomatic slow-acting drugs (SYSADs) treatment (Chondroitin, diacerein, glucosamine, soy and avocado unsaponifiables) in the last 3 months
  • An anticipated need for any OA related medication for the duration of the trial (Corticosteroids or hyaluronan injection, Oral corticotherapy, Arthroscopy, analgesics other than the authorized rescue treatments) which are forbidden during the trial
  • Arthroscopy in the last 6 months
  • Patients with known allergy to CS, GH, or intolerance to rescue treatment (Paracetamol and NSAIDs)
  • Patients with allergy to shellfish

Related to associated diseases

  • Severe and uncontrolled diseases (liver or renal failure, lung/heart severe disease, tumor, HIV….)
  • Anticipated need for any surgical or other invasive procedure during the trial including prosthesis in the target knee Related to patients
  • Artialis (study coordinator) or Bioiberica (Sponsor) 's employees
  • Participation to a therapeutic clinical trial in the last 3 months
  • Under guardianship or judicial protection
  • Pregnancy, breastfeeding, planned conception
  • Women without menopause or tubal ligation and without contraception

Related to MRI

  • Unable to receive gadopentetate contrast agent injection because of contraindications:
  • Acute or chronic severe renal insufficiency (a glomerular filtration rate < 30 mL/min/1.73m2); or
  • Acute renal insufficiency of any severity due to the hepato-renal syndrome or in the peri-operative liver transplantation period.
  • Known anaphylactic reactions to Gadolinium or related substances
  • Risk groups for MRI scanning due to magnetic field or contrast agent: Metal in body: Pacemaker / Automatic Implantable Cardioverter Defibrillators / Implantable Cardioverter Defibrillators (coronary defibrillator), Nervus vagus stimulator, Artificial heart valve (depending on type), Metal clips on cerebral arteries or veins, Metal particles in eye, Port-a-cath, Metal stents, Hydrocephalic pump / insulin pump, Metal implants; f/e screws, prostheses, piercings.
  • Claustrophobia, or serious mobility problem (Parkinson, tremors)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02821468


Contacts
Contact: Marta Herrero +34934904908 mherrero@bioiberica.com

Locations
Belgium
CHU Brugmann Recruiting
Bruxelles, Belgium
Contact: Anieska GIERASIMOWICZ - FONTANA       mherrero@bioiberica.com   
Sponsors and Collaborators
Bioiberica
Artialis
Investigators
Study Director: Josep Vergés Bioiberica

Responsible Party: Bioiberica
ClinicalTrials.gov Identifier: NCT02821468     History of Changes
Other Study ID Numbers: CL/BIO/2015-005 V5
First Posted: July 1, 2016    Key Record Dates
Last Update Posted: July 1, 2016
Last Verified: June 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Additional relevant MeSH terms:
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Acetaminophen
Cyclooxygenase 2 Inhibitors
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antipyretics
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Anti-Inflammatory Agents
Antirheumatic Agents